YOLFTbeta
Sinopep-Allsino Biopharmaceutical Co. Ltd. A

Sinopep-Allsino Biopharmaceutical Co. Ltd. A

688076 · SHG · Healthcare / Biotechnology

27.58CNY-0.58 (-2.06%)

Price History

Full chart

Market Stats

Previous Close28.16
Open28.11
Day Range27.50 – 28.18
52-Week Range25.70 – 41.26
Volume1.76M
Market Cap9.41B
P/E (TTM)39.68
Forward P/E0.00
EPS0.75
Dividend Yield1.18%
Beta0.26
50-Day Avg27.97
200-Day Avg30.96

About

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was founded in 2009 and is headquartered in Hangzhou, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Ziquan Tong
  • Employees2.36K
  • HeadquartersNo. 1378 Wenyi West Road, Hangzhou, China, 311121, China
  • Websitehttps://www.sinopep.com

Leadership

  • Mr. Ziquan TongGM & Chairman · b. 1970
  • Mr. Wei DingFinancial Director · b. 1983
  • Mr. Xiaohua LiSenior Vice President · b. 1981
  • Mr. Guoqiang ShiSenior Vice President · b. 1961
  • Ms. Zhou HuaSecretary of Board · b. 1978
  • Dr. Jianjun Jiang Ph.D.Vice President · b. 1956

Financials

Income Statement

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--8.78M8.51M228.87M255.53M371.53M566.87M643.87M651.29M1.03B1.62B1.94B
Growth (%)----3.05%+2589.64%+11.65%+45.40%+52.58%+13.58%+1.15%+58.69%+57.21%+19.57%
Cost of Revenue425.91K593.70K7.53M6.34M90.71M108.63M179.93M249.55M306.30M307.94M444.27M575.05M725.75M
Gross Profit-425.91K-593.70K1.25M2.17M138.16M146.90M191.60M317.32M337.57M343.36M589.28M1.05B1.94B
Gross Margin--14.21%25.51%60.37%57.49%51.57%55.98%52.43%52.72%57.02%64.61%100.00%
Operating Expense16.07M25.30M31.60M77.89M81.56M115.47M142.02M173.51M209.26M218.50M399.62M601.53M1.54B
Operating Income-16.50M-25.89M-30.36M-75.72M56.60M31.44M49.58M143.82M128.31M124.85M189.67M448.22M400.05M
Operating Margin---345.87%-889.88%24.73%12.30%13.35%25.37%19.93%19.17%18.35%27.59%20.59%
EBITDA-10.31M-15.70M-15.51M-58.80M83.42M64.89M102.88M229.86M213.64M231.35M320.99M675.49M553.78M
EBITDA Margin---176.76%-691.01%36.45%25.40%27.69%40.55%33.18%35.52%31.06%41.57%28.50%
Net Income-13.64M-25.16M-30.15M-74.80M41.93M43.91M48.61M123.44M115.39M129.11M162.94M404.39M327.00M
Net Income Margin---343.55%-879.02%18.32%17.18%13.08%21.78%17.92%19.82%15.76%24.89%16.83%
R&D1.54M3.57M-15.52M17.66M35.12M47.74M60.53M63.09M69.47M124.89M227.45M251.92M
R&D as % of Total Revenue---182.38%7.72%13.74%12.85%10.68%9.80%10.67%12.08%14.00%12.97%
Interest Expense--4.94M5.25M7.58M9.64M7.84M12.59M6.28M9.44M16.09M35.10M65.46M
Interest Expense % of Total Revenue--56.30%61.67%3.31%3.77%2.11%2.22%0.97%1.45%1.56%2.16%3.37%

Balance Sheet

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets166.81M151.58M196.67M160.11M611.47M1.05B1.24B1.40B2.13B2.52B3.55B5.08B6.74B
Total Liabilities163.12M173.05M123.35M125.16M290.27M265.47M405.54M429.55M318.14M597.41M1.36B2.40B3.74B
Total Equity3.69M-21.47M73.32M34.95M321.20M778.40M834.29M963.34M1.81B1.91B2.17B2.66B2.99B
Cash9.71M4.07M34.00M1.79M24.45M192.22M58.10M69.71M591.88M399.96M749.08M571.39M913.79M
Total Debt97.03M38.00M71.70M105.94M132.48M88.87M200.59M251.72M83.65M320.19M849.69M1.51B-
Net Debt87.32M33.93M37.70M104.14M108.03M-103.35M142.49M182.01M-508.23M-79.77M100.61M943.38M1.43B

Cash Flow

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow43.67M68.18M-112.62M-21.95M11.11M96.06M46.14M141.38M180.75M29.29M350.21M400.12M681.24M
Investing Cash Flow-24.63M-9.69M-12.07M-11.13M-47.76M-210.31M-275.71M-163.18M-236.93M-449.74M-662.21M-1.39B-
Financing Cash Flow-13.41M-64.13M154.63M875.57K54.58M284.48M98.59M39.50M534.89M236.91M631.90M799.75M-
Capital Expenditure24.63M9.69M12.07M11.14M73.34M197.48M276.39M111.28M233.36M438.36M660.64M1.09B1.37B
Free Cash Flow19.04M58.49M-124.70M-33.09M-62.23M-101.43M-230.25M30.10M-52.61M-409.07M-310.43M-690.01M-685.77M
Dividends Paid6.59M5.10M4.42M-59.11M8.38M4.47M11.63M6.04M31.98M57.61M118.75M239.60M
FCF to OCF43.60%85.79%110.72%150.74%-560.11%-105.59%-499.07%21.29%-29.11%-1396.52%-88.64%-172.45%-100.66%
Dividend Paid to FCF34.58%8.71%-3.55%--94.99%-8.27%-1.94%38.65%-11.49%-7.82%-18.56%-17.21%-34.94%

Earnings

Report DateOct 25, 2021Feb 28, 2022Apr 27, 2022Aug 29, 2022Oct 24, 2022Feb 27, 2023Apr 21, 2023Aug 20, 2025Oct 22, 2025Dec 31, 2025Apr 29, 2026
EPS Estimate-------0.570.410.170.29
EPS Actual0.180.200.080.080.090.360.100.300.34-0.210.39
Surprise--------47.37%-17.07%-223.53%34.48%
TimingPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-market-Pre-market

Key Statistics & Ratios

Market Cap9.41B
Enterprise Value11.08B
Trailing P/E39.68
Forward P/E0.00
Price / Sales4.62
Price / Book2.98
EPS0.75
Book Value9.78
Revenue (TTM)2.03B
Gross Profit (TTM)1.07B
EBITDA801.76M
Profit Margin11.67%
Operating Margin25.01%
Return on Equity7.66%
Return on Assets4.28%
Shares Outstanding316.05M
Shares Float182.42M
Beta0.26
Dividend Yield1.18%
Dividend Rate0.35
Payout Ratio67.31%

Dividends

20261×
0.35Jun 12, 2026
20251×
0.57Jun 12, 2025
20242×
0.07Sep 10, 20240.29Jun 17, 2024
20231×
0.14Jun 30, 2023
20221×
0.11Jun 9, 2022

Stock Splits

  • Jun 12, 20251.4:1